Company Overview and News
2018-09-07 seekingalpha - 4
Halvorsen's 13F portfolio value increased from $16.61B to $17.47B. The number of positions increased from 58 to 60.
ATHTF CNC AVXS ILMN CVS CRM EDIT AMZN MELI AET AXON OLN GE TMUSP ANAB TMUS CTLR ABEO UTX LNC GOOGL CTLT JT ABUS 500180 AHBIF MSFT NTES CLR HBI ADS JD WFCNP DCPH EIDX FB CP JAZZ MYOV TMO LEN WDC MOMO NFLX PE LEN.B GOOG MPC CLF ECA CP HDFCBANK BIDU DIS WFC MIDD ECN BUD GEC EFX TDG ANTM ECA COL DWDP X PTEN V XRAY IQ MU HDB GNE ADSK ABEOW ANTX
Document UNITED STATES
Earnings/Revenues Quarterly adjusted earnings came in at $1.63 per share, beating the Zacks Consensus Estimate of $1.60. However, the bottom line came in higher than the year-ago tally of $1.39 per share. Net sales in the reported quarter came in at $668.1 million, up 15.3% year over year. The top line also outpaced the Zacks Consensus Estimate of $651 million. The upswing was driven by acquisition benefits, Accounting Standards Codification 606 adoption, and favorable foreign currency-translation impact.
MIDD AIMC ALG UCTI APOG UCTT
Middleby (MIDD - Free Report) came out with quarterly earnings of $1.63 per share, beating the Zacks Consensus Estimate of $1.60 per share. This compares to earnings of $1.39 per share a year ago. These figures are adjusted for non-recurring items.
VREX MIDD ELY IPGP RYB
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
2018-08-07 seekingalpha - 2
Warren Buffett, the most quoted investor in America, is known for saying, "It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price." Every time I see that quote, The Middleby Corporation (MIDD) is one of the companies that passes through my mind. While Buffett does not own Middleby, the industry leader in commercial kitchen equipment possesses many qualities that would make it a great Buffett stock.
MIDD ITW WBT
2018-07-27 investorplace - 4
With automated technologies, the domain of fantasy and science-fiction is steadily becoming not only reality, it’s becoming the new norm. The robotic revolution has dramatically altered the economic landscape, driving productivity primarily in manufacturing and in many other sectors. As a result, automation stocks are virtual necessities for your portfolio.
LMT MIDD A CGNX CTRL ISRG EKSO ABB TER HON AAPL EMR OII BRKS ROK
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$Q," P(&]B:@T\/"],:6YE87)I>F5D(#$O3" R M,C Y-38O3R Q,3(O12 Q,#8U-#4O3B [email protected],C(P-C [email protected]@6R [email protected]@,C(Q M73X^#65N9&]B:@[email protected](" @(" @(" @(" @#0HQ,C<@,"!O8FH-/#PO1&5C;V1E M4&%R;7,\/"]#;VQU;6YS(#4O4')E9&EC=&]R(#$R/CXO1FEL=&5R+T9L871E M1&5C;V1E+TE$6SQ#0D(V,T)%,# Q0S$R.#0U0C8S-C8P030Q0D1$13DW,SX\ M14%"04(X,$%#.3$P0D4T1D(U-T$Y03E$0S X,#DV0C ^72]);F1E>%LQ,3 @ M-#)=+TEN9F\@,3 Y(# @4B],[email protected]@.
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ Schedule 13G ________________ INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* The Middleby Corporation (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 596278101 (CUSIP Number) Ju
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to MIDD / Middleby Corp. (The) on message board site Silicon Investor.
as of ET